Ladda ner presentationen
1
Lymfom Mats Jerkeman
2
Lymfom Översikt Diffust storcelligt B-cellslymfom Follikulärt lymfom
Burkittlymfom Mantelcellslymfom Hodgkinlymfom T-cellslymfom
3
Immunsystemet
4
B-cellens utveckling Antigen KLL Myelom Pre-B- ALL KLL Mantel cells
Minnescell KLL Prekursor B-cell Naiv B-cell Centrocyt Centroblast Plasmacell Benmärg Blod Mantelzon Germinalcentrum Blod/benmärg Antigen Myelom Pre-B- ALL KLL Mantel cells lymfom Follikulärt lymfom Diffust Storcelligt B-cells lymfom
6
Lymfom - symptom Lymfkörtel svullnad Tumör i annat organ B-symptom
Feber Svettningar Viktnedgång
7
Kvinna, 45 år Sedan 1 år 1 cm stor knuta vä ljumske
Sedan 1 månad 2 till, ökar snabbt i storlek Trött, viktnedgång 8 kg Blodstatus normalt Åtgärd?
8
Nytillkommen förstorad lymfkörtel
Primärvård Nytillkommen förstorad lymfkörtel Remiss för finnålspunktion, med frågeställning lymfom Labprover: Hb, V, diff, trc, LD
9
Om finnålspunktion bekräftar lymfommisstanke
Remiss Onkolog – (Malmö/Lund) Hematolog(övriga sjukhus i regionen) Beställ samtidigt CT hals, thorax, buk(?)
10
Utredning hos onkolog/hematolog
Röntgenologisk (CT thorax, buk, bäcken) Benmärg (biopsi, utstryk, flödescytometri) S-LD, urat Vid symptom: utredning av CNS, skelett
11
Stadieindelning - Ann Arbor
Stadium I en lymfkörtelstation Stadium II >1 lymfkörtelstation, samma sida av diafragma Stadium III >1 lymfkörtelstation, bägge sidor om diafragma Stadium IV Utbrett extranodalt engagemang (ex benmärg, lever)
12
Kvinna 45 år Finnålspunktion: kappamonoklonala celler, med hög Ig-täthet och CD19+/CD20+/CD5-/CD10+/CD23+ Remitteras till onkolog Lymfkörtelbiopsi: follikulärt lymfom, grad 1
13
Kadin, M. ASH Image Bank 2003;2003:100698
Diffust storcelligt B-cellslymfom Kadin, M. ASH Image Bank 2003;2003:100698
14
B-cellens utveckling Antigen DLBCL Memory B-cell Precursor B-cell
Naive B-cell Centrocyte Centroblast Plasma cell Bone marrow Blood Germinal centre Generation of antibody diversity in mature B cells. The antigen binding site of antibodies are created in immature B cells by the random assembly of variable (V), diversity (D), and joining (J) segments into one coding exon by a process termed V(D)J rearrangement. This process creates a very large repertoire of antibodies with different specificities. Unfortunately, because these antibodies are created randomly, most antibodies that are generated bind to antigen with low affinity. In order to neutralize and clear pathogens and toxins from the circulation, B-cells must produce and secrete antibodies of higher affinity and of different classes. Following exposure to antigen, the V regions of the antibody genes acquire many base changes that result in antibodies that bind with higher affinities to their respective antigens. This phenomenon is achieved by the somatic hypermutation process in mice and humans and immunoglobulin gene conversion in chickens (Figure 1). The constant region of the antibody gene encodes the remaining part of the antibody molecule and is responsible for carrying out the effector functions of the antibody. Constant regions, which define the antibody class, can be replaced with other constant regions by the class switch recombination process (Figure 1), thereby changing the antibody effector functions without changing the antigen binding site. Blood/bone marrow Antigen DLBCL
15
Basala data Medianålder 70 år 5-års överlevnad DLBCL i Sverige 50%
Kön 5-års överlevnad DLBCL i Sverige 50% Kv Män
16
Prognosfaktorer Ålder Performance Status Stadium
Extranodala manifestationer S-LD
17
DLBCL - IPI 1 2 3 4 5
18
DLBCL - Ålder 0-40 år 40-60 år 60-70 år 70-80 år >80 år
19
Behandling DLBCL - historik
1976 CHOP Cyklofosfamid Doxorubicin Vincristin Prednison
20
Rituximab Antikropp mot CD20
CD20 alla B-celler (förutom prekursor B och plasmaceller) Ger apoptos, CDC, ADCC Sensitiserar för cytostatika
21
R-CHOP > CHOP
22
Recidivbehandling Kurativt syfte: annan kemoterapi, ex DHAP, GDP
Mål: respons konsolidering med högdosbehandling med autologt stamcellsstöd (<70 år) – 20% bot Palliativt syfte: klorambucil, rituximab, XRT
23
Follikulärt lymfom
24
Follikulärt lymfom t(14;18)
Överuttryck av BCL2 - hämmare av apoptos
25
B-cellens utveckling Antigen FL Memory B-cell Precursor B-cell
Naive B-cell Centrocyte Centroblast Plasma cell Bone marrow Blood Germinal centre Generation of antibody diversity in mature B cells. The antigen binding site of antibodies are created in immature B cells by the random assembly of variable (V), diversity (D), and joining (J) segments into one coding exon by a process termed V(D)J rearrangement. This process creates a very large repertoire of antibodies with different specificities. Unfortunately, because these antibodies are created randomly, most antibodies that are generated bind to antigen with low affinity. In order to neutralize and clear pathogens and toxins from the circulation, B-cells must produce and secrete antibodies of higher affinity and of different classes. Following exposure to antigen, the V regions of the antibody genes acquire many base changes that result in antibodies that bind with higher affinities to their respective antigens. This phenomenon is achieved by the somatic hypermutation process in mice and humans and immunoglobulin gene conversion in chickens (Figure 1). The constant region of the antibody gene encodes the remaining part of the antibody molecule and is responsible for carrying out the effector functions of the antibody. Constant regions, which define the antibody class, can be replaced with other constant regions by the class switch recombination process (Figure 1), thereby changing the antibody effector functions without changing the antigen binding site. Blood/bone marrow Antigen FL
26
Klinik Stillsam, kronisk sjukdom Ej botbar
Behandling endast vid symptom Kan transformera till DLBCL (ca 10%)
27
FL Överlevnad
28
Behandling Rituximab R-Bendamustin R-CHOP
29
Burkittlymfom Denis Burkitt Uganda 1958 Michael Epstein, Yvonne Barr
30
Burkittlymfom Sverige: ca 15 patienter/år, B-ALL 2-5/år Endemisk
EBV + malaria HIV-relaterad Spontan Ofta engagemang i buk, benmärg, CNS (1/6) Sverige: ca 15 patienter/år, B-ALL 2-5/år
31
Burkittlymfom - Behandling
Extremt känslig för alkylerare (ctx) Tidiga stadier 80% bot singel-dos ctx Tumörlyssyndrom! CNS-profylax (HDMTX) Hög dosintensitet, kort behandling (3 mån) God prognos
32
Burkittlymfom - överlevnad
33
Mantelcellslymfom Äldre män (75% >65 år, 70% män)
Vanliga extranodala lokaler: Gastrointestinalkanalen (lymfomatoid polypos) ca 30% Benmärg Waldeyer, mjälte
34
Mantelcellslymfom t(11;14) Immunhistokemi cyklin-D1 FISH FCM: CD5+
35
R R RR MCL-1 TRIAL 1996-2000 MCL-2 TRIAL 2000-2006 B E A M/C B E A M/C
INDUCTION RE- STAGE STEM-CELL HARVEST REINFUSION B E A M/C Maxi C H O P Maxi C H O P Maxi C H O P Maxi C H O P Week: MCL-2 TRIAL INDUCTION RE- STAGE STEM-CELL HARVEST REINFUSION R R RR B E A M/C Maxi C H O P A r a C Maxi C H O P A r a C Maxi C H O P A r a C Week: AraC: 4 Infusions: < 60 years 3g/m2, > 60 years 2g/m2
36
Nordic MCL2
37
Hodgkinlymfom Incidenstopp i 20 års åldern, samt i 60 årsåldern.
38
Hodgkinlymfom -historik
50-talet Strålbehandling – mantelbehandling God behandlingseffekt Långtidsbiverkningar Sekundära maligniteter Klaffstenoser Coronarstenoser Muskelatrofi
40
HL - behandling Stadium I-IIA Stadium IIB-IV
ABVD x strålbehandling 30 Gy Stadium IIB-IV ABVD x 6-8 BEACOPP
41
HL Överlevnad
42
PET PET is the most important event in HL management in last decades. In other lymph PET has est for assess resp after compl therapy, but has turned out to be more probl in detect of early response (false positives). In HL repeatedly reliable, usually after 2 cycles.
43
PET för Hodgkinlymfom Responsutvärdering
Standard Tidig prediktion (efter 2 cykler) Experimentellt
44
Responsstyrd behandling
PET efter 2 cykler Positiv – eskalering Negativ – kortare behandling
45
T-cellslymfom Nodala Extranodala Leukemiska Kutana
Anaplastiskt storcelligt lymfom (ALCL Angioimmunoblastiskt T-cellslymfom Perifert T-cells lymfom, ej närmare specificerat Extranodala NK/T-cellslymfom av nasal typ T-cellslymfom, enteropatityp Hepatospleniskt T-cellslymfom Subkutant pannikulit-liknande T-cellslymfom Leukemiska Prekursor T-lymfoblastiskt lymfom (T-LBL) T-cell prolymfocytleukemi (T-PLL) Granulär lymfatisk leukemi (LGL) Adult T-cellsleukemi /lymfom Kutana Blastiskt NK-cellslymfom Mycosis fungoides (MF) och Sezarys syndrom (SS) Primärt kutant storcelligt anaplastiskt lymfom (C-ALCL) Lymfomatoid papulos (LyP)
46
Lymfom Stort antal skilda sjukdomar Många olika presentationer
Finnålspunktion ger vägledning Remiss onkolog/hematolog
Liknande presentationer
© 2024 SlidePlayer.se Inc.
All rights reserved.